ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation

These findings support the clinical development of ROSE12 as a tumor-selective Treg-depleting immunotherapy with potential efficacy in programmed cell death protein-1/PD-L1 therapy-resistant patients. The favorable safety profile was attributed to the ATP-dependent binding mechanism that restricts activity to the high-ATP tumor microenvironment. ROSE12 is currently being evaluated in phase I clinical trials (NCT05907980).

Authors

Nozomi Fujisawa
Tomoyuki Igawa (ORCID: https://orcid.org/0000-0003-0097-8220)
Otoya Ueda
Takehisa Kitazawa (ORCID: https://orcid.org/0000-0002-4958-7936)
Tomochika Matsushita
Junko Shinozuka (ORCID: https://orcid.org/0009-0002-3380-0760)
S. Sakaguchi
K. Tatsumi
Honoka Tanno
Masahiko Nanami
Yukari Nishito (ORCID: https://orcid.org/0000-0002-9331-4820)
Masaki Honda (ORCID: https://orcid.org/0000-0001-5526-2591)
Hiroaki Susumu
Chika Ogami (ORCID: https://orcid.org/0000-0002-2493-9616)
Yuri Ikuta
Yasunori Komori
Chie Kato (ORCID: https://orcid.org/0000-0001-8603-3759)
Tetsuya Wakabayashi (ORCID: https://orcid.org/0000-0001-9547-1291)
Kenji Kashima (ORCID: https://orcid.org/0000-0001-8460-2102)
Yutaka Matsuda (ORCID: https://orcid.org/0009-0008-8359-3791)
Tatsuya Kibayashi
Toshiaki Tsunenari (ORCID: https://orcid.org/0009-0009-0055-6766)
Kenji Nakagawa
Hiroaki Wakatsuki
Saki Michisaka
Chiyomi Kubo
Hiroaki Nagano (ORCID: https://orcid.org/0000-0002-7074-3315)
Hitoshi Katada
Momoko Miura-Okuda
Hiroki Hayashi
Ami Ito
Mika Endo
Moe Yoshimoto
Yasushi Tomii
Shun Shimizu
Takayuki Nemoto
Mika Kamata-Sakurai
Masaki Kamimura
Hiroshi Tanaka
Naoko A Wada
Hiroko Konishi
Shunichiro Komatsu
Masaki Yamazaki

Institutions

Chugai Pharma (United States) (US)
The University of Osaka (JP)

Publication Details

Journal: Journal for ImmunoTherapy of Cancer
Published: 2026-01-01
DOI: https://doi.org/10.1136/jitc-2025-013397
Primary Topic: Cancer Immunotherapy and Biomarkers
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Chugai Pharmaceutical

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation

Nozomi Fujisawa, Tomoyuki Igawa, Otoya Ueda, Takehisa Kitazawa, Tomochika Matsushita, Junko Shinozuka, S. Sakaguchi, K. Tatsumi, Honoka Tanno, Masahiko Nanami, Yukari Nishito, Masaki Honda, Hiroaki Susumu, Chika Ogami, Yuri Ikuta, Yasunori Komori, Chie Kato, Tetsuya Wakabayashi, Kenji Kashima, Yutaka Matsuda, Tatsuya Kibayashi, Toshiaki Tsunenari, Kenji Nakagawa, Hiroaki Wakatsuki, Saki Michisaka, Chiyomi Kubo, Hiroaki Nagano, Hitoshi Katada, Momoko Miura-Okuda, Hiroki Hayashi, Ami Ito, Mika Endo, Moe Yoshimoto, Yasushi Tomii, Shun Shimizu, Takayuki Nemoto, Mika Kamata-Sakurai, Masaki Kamimura, Hiroshi Tanaka, Naoko A Wada, Hiroko Konishi, Shunichiro Komatsu, Masaki Yamazaki

January 1, 2026article en

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation

Authors

Institutions

Publication Details

Funders

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.